AccuVAC-D001L

**AccuVAC-D001L** is an experimental **dendritic cell cancer vaccine** from **Defence Therapeutics** built on the company's **Accum** intracellular delivery platform. Preclinical reports describe it as a DC-based therapeutic vaccine designed to improve escape of Accum-linked tumor antigens from dendritic-cell endosomes, thereby enhancing antigen processing and presentation, strengthening effector T-cell priming, and promoting anti-tumor immunity. In published and company-reported preclinical work, AccuVAC-D001L showed activity in established **T-cell lymphoma** models and was also associated with a more inflamed tumor microenvironment, including increased tumor-infiltrating lymphocytes and a higher CD8 to Treg ratio. Defence has also described human manufacturing efforts for the broader AccuVAC-D001 program in support of planned early-phase clinical development in solid tumors such as **melanoma** and **breast cancer**, but clear evidence of clinical-stage advancement for the specific **AccuVAC-D001L** construct remains limited in the accessible sources.

Other names

AccuVAC-D001AccuVAC-D-001AccuVAC-D 001